DK2593463T3 - Formuleringer af rifaximin og anvendelser deraf - Google Patents

Formuleringer af rifaximin og anvendelser deraf Download PDF

Info

Publication number
DK2593463T3
DK2593463T3 DK11807418.6T DK11807418T DK2593463T3 DK 2593463 T3 DK2593463 T3 DK 2593463T3 DK 11807418 T DK11807418 T DK 11807418T DK 2593463 T3 DK2593463 T3 DK 2593463T3
Authority
DK
Denmark
Prior art keywords
rifaximin formulations
rifaximin
formulations
Prior art date
Application number
DK11807418.6T
Other languages
English (en)
Inventor
Jon Selbo
Jing Teng
Mohammed A Kabir
Pam Golden
Original Assignee
Salix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Inc filed Critical Salix Pharmaceuticals Inc
Application granted granted Critical
Publication of DK2593463T3 publication Critical patent/DK2593463T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK11807418.6T 2010-07-12 2011-07-12 Formuleringer af rifaximin og anvendelser deraf DK2593463T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36360910P 2010-07-12 2010-07-12
US41905610P 2010-12-02 2010-12-02
PCT/US2011/043769 WO2012009388A1 (en) 2010-07-12 2011-07-12 Formulations of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
DK2593463T3 true DK2593463T3 (da) 2020-08-10

Family

ID=45469785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11807418.6T DK2593463T3 (da) 2010-07-12 2011-07-12 Formuleringer af rifaximin og anvendelser deraf

Country Status (26)

Country Link
US (4) US20120077835A1 (da)
EP (2) EP3750526A1 (da)
JP (1) JP5943915B2 (da)
KR (1) KR101887004B1 (da)
CN (1) CN103228662B (da)
AU (1) AU2011279261B2 (da)
BR (1) BR112013000802B1 (da)
CA (1) CA2804635C (da)
CR (1) CR20130033A (da)
DK (1) DK2593463T3 (da)
EA (1) EA033370B1 (da)
ES (1) ES2801678T3 (da)
GE (1) GEP20227342B (da)
HU (1) HUE049986T2 (da)
IL (1) IL223725B (da)
LT (1) LT2593463T (da)
MX (1) MX345697B (da)
MY (1) MY165086A (da)
NZ (1) NZ605232A (da)
PL (1) PL2593463T3 (da)
PT (1) PT2593463T (da)
SG (2) SG186981A1 (da)
SI (1) SI2593463T1 (da)
TN (1) TN2012000611A1 (da)
WO (2) WO2012009388A1 (da)
ZA (1) ZA201300193B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
AU2012332211B2 (en) * 2011-11-02 2016-11-24 Salix Pharmaceuticals, Ltd. Methods for treating irritable bowel syndrome (IBS) and infections
AU2013212008A1 (en) 2012-01-25 2014-07-10 Alfa Wassermann S.P.A. Rifaximin derivative and uses thereof
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2757135B1 (en) 2013-01-18 2017-11-29 3M Innovative Properties Company Method of bonding parts to a vehicle by an acrylic foam tape
EP3065788A1 (en) * 2013-11-08 2016-09-14 Tyrx, Inc. Antimicrobial compositions and methods for preventing infection in surgical incision sites
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
ES2742106T3 (es) 2014-05-12 2020-02-13 Alfasigma Spa Nueva forma de cristal solvatado de rifaximina, producción, composiciones y usos de la misma
JP7024248B2 (ja) * 2016-09-01 2022-02-24 大正製薬株式会社 固形製剤
WO2018064472A1 (en) * 2016-09-30 2018-04-05 Salix Pharmaceuticals, Ltd. Solid dispersion forms of rifaximin
CN110621305A (zh) * 2017-07-24 2019-12-27 爱科思华制药研发有限责任公司 高载药量药物组合物
CN109453165B (zh) * 2018-10-16 2021-02-05 丹诺医药(苏州)有限公司 一种利福霉素-硝基咪唑偶联分子的固体分散体及其应用
CN109453166B (zh) * 2018-10-16 2021-03-12 丹诺医药(苏州)有限公司 一种利福霉素-喹嗪酮偶联分子的固体分散体及其应用
WO2020198136A1 (en) * 2019-03-22 2020-10-01 New York Medical College Use of rifaximin on circulating aged neutrophils in sickle cell disease
US20220378758A1 (en) 2019-09-24 2022-12-01 Bausch Health Ireland Limited Rifaximin liquid formulations
US20230141118A1 (en) * 2020-04-13 2023-05-11 Bausch Health Ireland Limited Methods of using solid dispersions of rifaximin for the treatment of sickle cell disease
CA3184054A1 (en) 2020-06-26 2021-12-30 Jacob Cole Targeted release rifaximin compositions
WO2022090490A1 (en) 2020-10-29 2022-05-05 Bausch Health Ireland Limited Rifaximin liquid formulations for use in the treatment of sickle cell disease
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
BR0210520A (pt) * 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de dispersões de fármacos amorfos misturados com polìmeros
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
BRPI0418330A (pt) * 2003-12-31 2007-05-02 Pfizer Prod Inc composições sólidas de drogas de solubilidade baixa e poloxámeros
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
DK1698630T3 (da) 2005-03-03 2014-12-08 Alfa Wassermann Spa Nye polymorfe former af rifaximin, fremgangsmåde for deres fremstilling og anvendelse deraf i de medicinske præparater
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
US20080095754A1 (en) * 2006-10-18 2008-04-24 Burke Susan E Ophthalmic compositions comprising diglycine
AU2008273699A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
DK2011486T3 (da) * 2007-07-06 2012-09-03 Lupin Ltd Farmaceutiske sammensætninger af rifaximin
KR100903618B1 (ko) * 2007-10-30 2009-06-18 삼성에스디아이 주식회사 플라즈마 디스플레이 패널
CN102015725B (zh) * 2008-02-25 2014-10-22 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US8486956B2 (en) * 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
PL2252148T3 (pl) * 2008-02-26 2019-09-30 Salix Pharmaceuticals, Ltd. Sposoby leczenia zespołu jelita drażliwego
EP2105130A1 (de) * 2008-03-25 2009-09-30 Ratiopharm GmbH Pharmazeutische Formulierung und Verfahren zu deren Herstellung
JP5756020B2 (ja) * 2008-12-10 2015-07-29 シプラ・リミテッド リファキシミン複合体
KR20200100215A (ko) 2009-10-27 2020-08-25 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
JP5717768B2 (ja) * 2010-03-10 2015-05-13 アッヴィ・バハマズ・リミテッド 固体組成物

Also Published As

Publication number Publication date
BR112013000802B1 (pt) 2021-08-31
ZA201300193B (en) 2019-07-31
BR112013000802A2 (pt) 2016-05-24
CN103228662B (zh) 2016-08-10
MY165086A (en) 2018-02-28
GEP20227342B (en) 2022-01-25
JP5943915B2 (ja) 2016-07-05
US20120077835A1 (en) 2012-03-29
KR20130098300A (ko) 2013-09-04
EP2593463A1 (en) 2013-05-22
EP3750526A1 (en) 2020-12-16
EP2593463A4 (en) 2014-04-23
US9737610B2 (en) 2017-08-22
CA2804635C (en) 2019-09-10
US20170333562A1 (en) 2017-11-23
KR101887004B1 (ko) 2018-08-09
SG10201505484RA (en) 2015-09-29
WO2012009388A1 (en) 2012-01-19
MX2013000522A (es) 2013-05-01
CR20130033A (es) 2013-04-29
SG186981A1 (en) 2013-02-28
PL2593463T3 (pl) 2020-11-02
US20200397904A1 (en) 2020-12-24
CA2804635A1 (en) 2012-01-19
PT2593463T (pt) 2020-09-17
US20150133482A1 (en) 2015-05-14
AU2011279261A1 (en) 2013-01-17
MX345697B (es) 2017-02-13
LT2593463T (lt) 2020-08-25
NZ605232A (en) 2015-09-25
CN103228662A (zh) 2013-07-31
SI2593463T1 (sl) 2020-10-30
EA033370B1 (ru) 2019-10-31
EP2593463B1 (en) 2020-05-06
WO2012009387A1 (en) 2012-01-19
EA201370018A1 (ru) 2013-09-30
IL223725B (en) 2020-03-31
AU2011279261B2 (en) 2016-03-31
ES2801678T3 (es) 2021-01-12
JP2013532633A (ja) 2013-08-19
HUE049986T2 (hu) 2020-11-30
TN2012000611A1 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
DK2593463T3 (da) Formuleringer af rifaximin og anvendelser deraf
DK3158991T3 (da) Formuleringer af bendamustin
DK2648742T3 (da) Formuleringer indeholdende saponiner og anvendelser deraf
DK2648809T3 (da) Naturlige formuleringer
DK2594567T3 (da) Heterocykliske alkynylbenzenforbindelser og anvendelser deraf
DK2542189T3 (da) Håndprotese
DK3246021T3 (da) Apixabanformuleringer
BR112012028556A2 (pt) Indóis
CR20130111A (es) Triazina-oxidiazoles
DE10170954T8 (de) Mikrowellendruckgarer
FI8622U1 (sv) Stolpsko
DK2642992T3 (da) Forbindelser og anvendelse deraf
DE102011002623A8 (de) Ventilsteuerzeitversteller
BR112013013459A2 (pt) guarda-chuva inflável
DE102010019119B8 (de) Cuttermesser
DE102010038420A8 (de) Reinigungungsvorrichtung
DE102010035554B8 (de) Fußtüröffner
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas
DK2407155T3 (da) Formuleringer af inecalcitol
DK2606569T3 (da) Piezomotor
DK2536591T3 (da) Advarselslysanordning; komponenter; og fremgangsmåder
BR112013009512A2 (pt) composição herbicida
ES1071902Y (es) Mecanismo de termosoldadura y precorte
BR112013013441A2 (pt) composição de adesivo-engomadura e métodos relacionados
FI9608U1 (fi) Formulaatiot